IICJ Paper Different Approaches to Pricing and Reimbursement of Innovative Pharmaceutical Products in Europe Renato Dellamano, President, Value Vector, Italy
Renato Dellamano, President, Value Vector, Italy

All aspects of the pharmaceutical market are heavily regulated due to the major public health implications related to the use of pharmaceutical products. Pricing and reimbursement of pharmaceutical products is the area posing the greatest level of challenge to pharmaceutical and biotech firms operating on a multinational basis. Each individual country is governed by its own pricing and reimbursement rules and procedures and - despite European legislation mandating transparency of decisions and harmonized timelines - the outcome of the various national pricing and reimbursement processes may vary dramatically both in terms of timing and results.
Author
Renato Dellamano
Renato Dellamano is the President of ValueVector, a consulting agency he founded in 2003 that provides strategic advice to companies operating in the healthcare field. One of the top experts worldwide in the field of pharmaceutical and biotech pricing and reimbursement, he accumulated more than twenty years of extensive business experience in the healthcare industry. Prior to founding ValueVector, Renato was the global Head of Strategic Pricing at the Headquarters of the Swiss pharmaceutical company Hoffmann-La Roche, in Basel. In the seven years he held this position, he was instrumental in developing global pricing and reimbursement strategies for pharmaceutical products in all the disease areas Roche had an interest in, including internally developed and in-licensed projects. Before heading the Strategic Pricing function, he spent almost two years as Global Controller of the Pharma Division of Hoffmann-La Roche, with responsibility on the Europe-Africa region. Previously, Renato had held senior managerial positions at the Italian Affiliate of Hoffmann-La Roche, in Milan, where – between 1989 and 1994 – he headed the Strategic Planning, the Pricing and Reimbursement and the Business Development functions. A Health Economist and a former professor of Hospital Management, he holds a degree in economics from the Bocconi University of Milan and specialized in Health Economics at the CERGAS - Center for Research on Health Care Management, in Milan.
Author
Renato Dellamano
Renato Dellamano is the President of ValueVector, a consulting agency he founded in 2003 that provides strategic advice to companies operating in the healthcare field. One of the top experts worldwide in the field of pharmaceutical and biotech pricing and reimbursement, he accumulated more than twenty years of extensive business experience in the healthcare industry. Prior to founding ValueVector, Renato was the global Head of Strategic Pricing at the Headquarters of the Swiss pharmaceutical company Hoffmann-La Roche, in Basel. In the seven years he held this position, he was instrumental in developing global pricing and reimbursement strategies for pharmaceutical products in all the disease areas Roche had an interest in, including internally developed and in-licensed projects. Before heading the Strategic Pricing function, he spent almost two years as Global Controller of the Pharma Division of Hoffmann-La Roche, with responsibility on the Europe-Africa region. Previously, Renato had held senior managerial positions at the Italian Affiliate of Hoffmann-La Roche, in Milan, where – between 1989 and 1994 – he headed the Strategic Planning, the Pricing and Reimbursement and the Business Development functions. A Health Economist and a former professor of Hospital Management, he holds a degree in economics from the Bocconi University of Milan and specialized in Health Economics at the CERGAS - Center for Research on Health Care Management, in Milan.
Company
Value Vector
Country
Italy More
Area of Law
Competition More
Business Sector
Healthcare More
Month Published
July 2007 More
Edition
Vol. 1, No. 1, Autumn 2007 More
    Go back to Library Search